Who are treatment Doxorubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ADM, Doxorubicin hydrochloride liposome, Daunorubicin/Idarubicin, Liposomal daunorubicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-doxorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

treatment Doxorubicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

treatment Doxorubicin (treatment Doxorubicin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthracycline chemotherapy agent. Area: Oncology.

phase 3 Anthracycline chemotherapy agent DNA (intercalating agent); Topoisomerase II Oncology Small molecule Live · refreshed every 30 min

Target snapshot

treatment Doxorubicin (treatment Doxorubicin) — Assistance Publique Hopitaux De Marseille. Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
treatment Doxorubicin TARGET	treatment Doxorubicin	Assistance Publique Hopitaux De Marseille	phase 3	Anthracycline chemotherapy agent	DNA (intercalating agent); Topoisomerase II
ADM	ADM	Italian Sarcoma Group	marketed	Anthracycline chemotherapy agent	Topoisomerase II; DNA
Doxorubicin hydrochloride liposome	Doxorubicin hydrochloride liposome	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	marketed	Anthracycline chemotherapy agent (liposomal formulation)	DNA topoisomerase II
Daunorubicin/Idarubicin	Daunorubicin/Idarubicin	Institute of Hematology & Blood Diseases Hospital, China	phase 3	Anthracycline chemotherapy agent	Topoisomerase II; DNA
Liposomal daunorubicin	Liposomal daunorubicin	University of Birmingham	phase 3	Anthracycline chemotherapy agent	Topoisomerase II, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthracycline chemotherapy agent class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Institute of Hematology & Blood Diseases Hospital, China · 1 drug in this class
Italian Sarcoma Group · 1 drug in this class
University of Birmingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). treatment Doxorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-doxorubicin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab